AstraZeneca prepares extra global vaccine trial amid growing scrutiny
CEO Pascal Soriot says he does not expect the additional trial to hold up regulatory approvals in the UK and EU, while clearance from the US FDA may take longer
26 November 2020 - 21:23
AstraZeneca is likely to conduct an additional global trial to assess the efficacy of its Covid-19 vaccine, according CEO Pascal Soriot, after current studies raised questions over its level of protection.
The new trial would be run instead of adding an arm to an ongoing US trial and would evaluate a lower dosage that performed better than a full amount in Astra’s studies. The company’s acknowledgment that the lower level was given in error fuelled concerns, and the new trial would be used to confirm whether the higher 90% efficacy rate stands...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.